Abbott Laboratories (ABT) announced that it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus or HBV in a patient's blood.
The company said that Abbott RealTime HBV assay is now available for laboratories that use the Abbott m2000 automated instrument system for molecular diagnostic testing.
The assay is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The assay can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatmen, the company said.
For comments and feedback: editorial@rttnews.com